23 completed, 11 recruiting, 6 active not recruiting, 5 terminated. 57 Phase 1, 24 Phase 2.
Follow Oropharyngeal Neoplasms: new trials by email Literature Review of Oropharyngeal Neoplasms trials Research Report on Oropharyngeal Neoplasms
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Proactively Intervening On Early Cranial Nerve Injury As A Delayed Sequela Of Oropharyngeal Cancer: A Randomized Feasibility Clinical Trial For Pro-Habilitation (proNERVE RCT) Prednisone, Ajovy, Manual Therapy - Cranial Nerve Injury, Oropharyngeal Cancer | Phase 1 | Not yet recruiting | M.D. Anderson Cancer Center | 48 | 2027-03-01 | 2026-09-21 |
| Testing the Addition of an Anti-Cancer Drug, Camonsertib, to Radiation Therapy for Recurrent Head and Neck Squamous Cell Carcinoma Biospecimen Collection, Camonsertib, Computed Tomography - Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Recurrent Head and Neck Squamous Cell Carcinoma | Phase 1 | Recruiting | National Cancer Institute (NCI) | 39 | 2027-02-13 | 2026-10-29 |
| Ficerafusp Alfa, Pembrolizumab, and Stereotactic Body Radiotherapy (SBRT) for Head and Neck Squamous Cell Carcinoma (HNSCC) Hypofractionated Stereotactic Body Radiotherapy (SBRT), Pembrolizumab, Ficerafusp alfa - Head and Neck Squamous Cell Carcinoma, HPV-Negative Squamous Cell Carcinoma | Phase 1 / Phase 2 | Not yet recruiting | Washington University School of Medicine | 45 | 2026-11-30 | 2026-11-03 |
| TMV Vaccine Alone or With Toripalimab-tpzi for Recurrent Head and Neck Squamous Cell Carcinoma TMV Vaccine, Toripalimab-tpzi - Squamous Cell Carcinoma of Head and Neck, Squamous Cell Carcinoma of Head and Neck (SCCHN) | Phase 1 | Recruiting | Metaclipse Therapeutics Corporation | 30 | 2026-10-01 | 2026-10-27 |
| Thermotherapy for Head and Neck Cancer Patients Thermotherapy, Radiotherapy, Concurrent chemoradiation - Head and Neck Cancer, Oropharyngeal Carcinoma | Phase 1 | Recruiting | Erasmus Medical Center | 30 | 2026-09-01 | 2026-09-02 |
| E7 T-cell Receptor (TCR) -T Cell Induction Therapy for Locoregionally Advanced HPV-associated Cancers E7 TCR-T cells, Aldesleukin - HPV-Associated Cervical Carcinoma, HPV-Related Carcinoma | Phase 1 / Phase 2 | Recruiting | Christian Hinrichs | 15 | 2025-08-11 | 2026-10-28 |
| TMV Vaccine Therapy Alone and With Pembrolizumab for the Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell Cancer Autologous Tumor Membrane Vesicles Vaccine, Biospecimen Collection, Computed Tomography - Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Metastatic Head and Neck Squamous Cell Carcinoma | Phase 1 | Recruiting | Emory University | 40 | 2025-05-08 | 2026-03-04 |
| PIRATES: Image-guided Hyper-fractioned Dose-escalation With Proton Therapy for Head and Neck Cancer Image guided hybrid hyper-fractioned dose escalation with proton therapy - Head and Neck Cancer, Oropharyngeal Cancer | Phase 1 | Recruiting | University Medical Center Groningen | 17 | 2025-05-01 | 2025-04-03 |
| Thermotherapy for Locally Advanced Head and Neck Cancer Thermotherapy, radiotherapy - Head and Neck Cancer, Oropharyngeal Carcinoma | Phase 1 | Active not recruiting | Erasmus Medical Center | 2 | 2025-05-01 | 2026-09-02 |
| Intratumoral Lidocaine Injection Before Oropharyngeal Cancer Surgery Lidocaine 1% Injectable Solution - Oropharyngeal Squamous Cell Carcinoma (OPSCCA), Oropharyngeal Cancer | Phase 1 | Recruiting | Ryan Carey | 30 | 2025-04-23 | 2026-05-12 |
| Autologous T Cells Targeting HPV16 HPV18 & Survivin in Patients With R/R HPV-related Oropharyngeal Cancers Fludarabine, Cyclophosphamide, NEXI-003 T cells - Oropharyngeal Cancer, Human Papilloma Virus | Phase 1 | Not yet recruiting | NexImmune Inc. | 36 | 2025-03-31 | 2024-01-16 |
| Phase 1/2 Study of Autologous SCG142 TCR T Cells in Patients With HPV16/52-positive Carcinoma SCG142, Cyclophosphamide, Fludarabine - HPV-Related Squamous Cell Carcinoma, HPV-Related Cervical Squamous Cell Carcinoma | Phase 1 / Phase 2 | Not yet recruiting | SCG Cell Therapy Pte. Ltd. | 66 | 2024-10-01 | 2024-07-17 |
| A Study to Evaluate Lenti-HPV-07 Immunotherapy Against HPV+ Cervical or Oropharyngeal Cancer Two IM injections Lenti-HPV-07, One IM injection Lenti-HPV-07 - HPV-Related Cervical Carcinoma, HPV Positive Oropharyngeal Squamous Cell Carcinoma | Phase 1 / Phase 2 | Recruiting | Theravectys S.A. | 72 | 2024-08-08 | 2026-02-02 |
| A Study of Concurrent Chemoradiation in Combination With or Without PD1 Inhibitor AB122 Adenosine 2a Receptor / Adenosine 2b Receptor Inhibitor AB928 Therapies in Locally Advanced Head and Neck Cancers Zimberelimab, Etrumadenant, Cisplatin - Head and Neck Cancer, Squamous Cell Carcinoma of Head and Neck | Phase 1 | Withdrawn | Jennifer Choe | 2023-12-31 | 2023-11-30 | |
| Two-cohort Study of Niraparib and Dostarlimab Plus (Chemo)RadIotherapy in Locally-Advanced Head and Neck Squamous Cell Carcinoma Dostarlimab, Niraparib, cisplatin plus radiotherapy - Head and Neck Squamous Cell Carcinoma | Phase 1 / Phase 2 | Active not recruiting | Grupo Español de Tratamiento de Tumores de Cabeza y Cuello | 34 | 2023-11-13 | 2026-06-04 |
| HRYZ-T101 TCR-T Cell for HPV-18 Positive Advanced Solid Tumor Fludarabine + Cyclophosphamide, HRYZ-T101 TCR-T Cell - Cervical Cancer, Head and Neck Squamous Cell Carcinoma | Phase 1 | Unknown | HRYZ Biotech Co. | 17 | 2023-03-21 | 2024-02-02 |
| Testing the Addition of Ipatasertib to Usual Chemotherapy and Radiation for Head and Neck Cancer Biopsy Procedure, Biospecimen Collection, Cisplatin - Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 | Phase 1 | Recruiting | National Cancer Institute (NCI) | 46 | 2022-09-19 | 2026-09-22 |
| Testing the Addition of an Anti-cancer Drug, BAY 1895344, With Radiation Therapy to the Usual Pembrolizumab Treatment for Recurrent Head and Neck Cancer Biospecimen Collection, Computed Tomography, Elimusertib - Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 7 | 2022-07-06 | 2026-08-21 |
| A Vaccine (PDS0101) Alone or in Combination With Pembrolizumab for the Treatment of Locally Advanced Human Papillomavirus-Associated Oropharynx Cancer Liposomal HPV-16 E6/E7 Multipeptide Vaccine PDS0101, Pembrolizumab, Computed Tomography - Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Human Papillomavirus-Related Carcinoma | Phase 1 / Phase 2 | Active not recruiting | Mayo Clinic | 20 | 2022-06-16 | 2026-10-07 |
| Testing the Addition of M3814 (Peposertib) to Radiation Therapy for Patients With Advanced Head and Neck Cancer Who Cannot Take Cisplatin Intensity-Modulated Radiation Therapy, Peposertib - Advanced Head and Neck Squamous Cell Carcinoma, Advanced Hypopharyngeal Squamous Cell Carcinoma | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 21 | 2021-12-20 | 2026-10-13 |
Showing 20 of 57. Sign in to see all of them.
Mouth Neoplasms (28) · Head and Neck Neoplasms (26) · Squamous Cell Carcinoma of Head and Neck (26) · Laryngeal Neoplasms (24) · Hypopharyngeal Neoplasms (23) · Uterine Cervical Neoplasms (11) · Nasopharyngeal Neoplasms (10) · Carcinoma (9) · Carcinoma, Renal Cell (8) · Salivary Gland Neoplasms (8) · Anus Neoplasms (7) · Carcinoma, Non-Small-Cell Lung (7) · Carcinoma, Squamous Cell (7) · Breast Neoplasms (6)
Otorhinolaryngologic Diseases (57) · Otorhinolaryngologic Neoplasms (57) · Pharyngeal Diseases (57) · Stomatognathic Diseases (57) · Neoplasms by Site (56) · Pharyngeal Neoplasms (56) · Neoplasms (53) · Neoplasms by Histologic Type (36) · Neoplasms, Glandular and Epithelial (35) · Head and Neck Neoplasms (31) · Mouth Diseases (30) · Respiratory Tract Diseases (29) · Respiratory Tract Neoplasms (28) · Carcinoma (27) · Laryngeal Diseases (23)
Cisplatin (12) · pembrolizumab (11) · Radiotherapy (8) · Biopsy (5) · Radiation (5) · Specimen Handling (5) · Cyclophosphamide (4) · Fluorouracil (4) · Magnetic Resonance Spectroscopy (4) · Paclitaxel (4) · fludarabine (4) · Gemcitabine (3) · Radiosurgery (3) · 1,2-diaminocyclohexaneplatinum II citrate (2) · Diathermy (2)
National Cancer Institute (NCI) (12) · Erasmus Medical Center (2) · Inhibrx Biosciences, Inc (2) · M.D. Anderson Cancer Center (2) · Memorial Sloan Kettering Cancer Center (2) · Ohio State University Comprehensive Cancer Center (2) · Abramson Cancer Center at Penn Medicine (1) · Celldex Therapeutics (1) · Christian Hinrichs (1) · Copenhagen University Hospital, Rigshospitalet (1) · Emory University (1) · Grupo Español de Tratamiento de Tumores de Cabeza y Cuello (1) · Guy's and St Thomas' NHS Foundation Trust (1) · HRYZ Biotech Co. (1) · Hookipa Biotech GmbH (1)
United States (44) · Netherlands (4) · Canada (3) · South Korea (2) · Spain (2) · China (1) · Denmark (1) · Germany (1) · Singapore (1) · Taiwan (1) · United Kingdom (1)
Charalampos Floudas, M.D. (2) · Michiel Kroesen, MD, Dr. (2) · Yvonne M Mowery (2) · Amit Agrawal (1) · Anthony Fyles, MD (1) · Athanassios Argiris, MD (1) · Charlotte Lynggaard, MD (1) · Christian S Hinrichs, M.D. (1) · Christian S Hinrichs, MD (1) · Christopher Pack, PhD (1) · David M. Routman, M.D. (1) · David R. Spriggs, MD (1) · Dominic Moon, MD (1) · Dong M. Shin, MD, FACP, FAAAS (1)
PMID 23083061, PMID 25965900, PMID 26062933, PMID 26186556, PMID 26611425, PMID 28498880, PMID 30850872, PMID 32479189, PMID 33161013, PMID 39976981, PMID 40116923, PMID 40404202, PMID 41724817
UM1CA186690 (2), 2009 (1), 2018 (1), 2019 (1), N01CM62201 (1), P30CA014520 (1), P30CA138292 (1), P50CA097007 (1), R01CA262123 (1), U10CA031946 (1), U10CA180821 (1), U10CA180868 (1), UM1CA186644 (1)